| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Thursday’s Close |
|---|---|---|---|---|---|
| AZN | Astrazeneca PLC | $37.56 | $95.16B | Downtrend |
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
http://www.zacks.com/stock/news/412897/aveo-pharmaceuticals-aveo-q1-earnings-revenues-miss-mark?cid=CS-ZC-FT-412897
May 11, 2019 - AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
0
AVEO Pharmaceuticals (AVEO) Q1 Earnings & Revenues Miss Mark
http://www.zacks.com/stock/news/412859/aveo-pharmaceuticals-aveo-q1-earnings-revenues-miss-mark?cid=CS-ZC-FT-412859
May 10, 2019 - AVEO Pharmaceuticals (AVEO) discourages investors in Q1 with wider-than-expected loss as well as a revenue miss. Also, Fotivda NDA gets delayed as the FDA was dissatisfied with the OS data.
0
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug
http://www.zacks.com/stock/news/412433/pharma-stock-roundup-agn-nvo-report-q1-earnings-nvs-to-buy-takedas-eye-drug?cid=CS-ZC-FT-412433
May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.
0
AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
http://www.zacks.com/stock/news/406072/aveo-pharmaceuticals-aveo-to-post-q1-earnings-whats-up?cid=CS-ZC-FT-406072
Apr 30, 2019 - During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.
0
Better Big Pharma Stock: AbbVie vs. AstraZeneca
https://www.fool.com/investing/2019/04/29/better-big-pharma-stock-abbvie-vs-astrazeneca.aspx?source=iedfolrf0000001
Apr 29, 2019 - These A-list drugmakers must both contend with expiring patents, new drug uncertainties, and hungry competitors. But they're in different stages of their cyclical journeys.
0
AstraZeneca PLC (AZN) Q1 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/04/26/astrazeneca-plc-azn-q1-2019-earnings-call-transcri.aspx?source=iedfolrf0000001
Apr 26, 2019 - AZN earnings call for the period ending March 31, 2019.
0
AstraZeneca PLC (AZN) CEO Pascal Soriot on Q1 2019 Results - Earnings Call Transcript
https://seekingalpha.com/article/4257301-astrazeneca-plc-azn-ceo-pascal-soriot-q1-2019-results-earnings-call-transcript?source=feed_sector_healthcare
Apr 26, 2019 - AstraZeneca PLC (NYSE:AZN) Q1 2019 Earnings Conference Call April 26, 2019, 07:00 ET Company Participants Pascal Soriot - CEO & Executive Director David Fredrickson - EVP & President, Oncology
0
AstraZeneca's (AZN) Q1 Earnings Beat, New Drugs Drive Sales
http://www.zacks.com/stock/news/404479/astrazenecas-azn-q1-earnings-beat-new-drugs-drive-sales?cid=CS-ZC-FT-404479
Apr 26, 2019 - AstraZeneca (AZN) beats earnings and sales estimates in the first quarter. New drugs, especially cancer drugs, drive revenues.
0
Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales
http://www.zacks.com/stock/news/404335/sanofi-sny-q1-earnings-top-genzyme-vaccines-drive-sales?cid=CS-ZC-FT-404335
Apr 26, 2019 - Sanofi's first-quarter 2019 results were mixed as it beat estimates for earnings but missed the same for sales.
0
Bayer (BAYRY) Q1 Earnings Beat Estimates, Revenues Up Y/Y
http://www.zacks.com/stock/news/403595/bayer-bayry-q1-earnings-beat-estimates-revenues-up-y-y?cid=CS-ZC-FT-403595
Apr 25, 2019 - Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
0
Page 1>